SEARCH

Click on the blue print button to print or save the monograph as a PDF. Search for another drug by typing into the box above.

$2.17 per vial

Amoxicillin / Amoxycillin

Editor: Updated Class:

ADMINISTRATION ROUTES:

Oral; Nasogastric; Intravenous

ALTERNATIVE NAMES:

Apo-Amoxi, Ospamox, Ranbaxy-Amoxi, Ibiamox

ICU INDICATIONS:

  1. Treatment of infections caused by susceptible organisms.

  2. Empirical treatment to cover Enterococcus.

PRESENTATION AND ADMINISTRATION:

INTRAVENOUS:

Compatible with the following intravenous fluids:

Sodium chloride 0.9%; Glucose 5%

Note: amoxicillin is less stable in solutions that contain glucose so it is preferable to avoid these solutions.

1 g vial (powder)

Store at room temperature.

Reconstitution:

Reconstitute to total of 5 mL using water for injection if part dose is required (making concentration of 200 mg/mL). Reconstituted solution is stable for up to 1 hour at room temperature.

Can be administered peripherally or centrally.

Intravenous injection:

Administer reconstituted solution over 3-4 minutes.

Intravenous intermittent infusion:

Further dilute to 50 mL using either of the compatible fluids listed below. Administer over 30 minutes.

Once diluted, store at room temperature for up to 1 hour when diluted with glucose 5% or up to 6 hours when diluted with sodium chloride 0.9%.

ORAL / NASOGASTRIC:

Amoxycillin 250 mg capsules

Amoxycillin 500 mg capsules

Amoxicillin 125 mg/5 mL oral liquid, powder for

Amoxicillin 250mg/5 mL oral liquid, powder for

Dispersing the capsules is preferred for nasogastric administration.

Store the capsules and powder for oral liquid at room temperature.

Oral liquid should be stored refrigerated and solution discarded 14 days after being made up.

DOSAGE:

INTRAVENOUS:

Treatment of Listeria meningitis or Enterococcus faecalis infective endocarditis:

2 g intravenously six times a day

Other indications:

1-2 g intravenously four times a day

ORAL:

1 g orally three to four times a day

DOSAGE IN RENAL FAILURE AND RENAL REPLACEMENT THERAPY:

Dose in renal impairment

GFR (mL/min) DOSE
>20 Dose as in normal renal function.
10-20 2 g three times a day
<10 1 g three times a day

Dose In renal Impairment for treatment of Listeria meningitis or Enterococcus faecalis infective endocarditis

GFR (mL/min) DOSE
>30 Dose as in normal renal function.
10-30 2 g four times a day
<10 2g three times a day

Dose in renal replacement therapy

MODALITY DOSE
CAPD 1 g three times a day, up to 2 g three times a day may be used for high dose indications
HD 1 g three times a day, up to 2 g three times a day may be used for high dose indications
CVVHDF Dose as in normal renal function.

DOSAGE IN HEPATIC IMPAIRMENT:

Dose as in normal liver function.

DOSAGE IN PAEDIATRICS:

INTRAVENOUS:

Severe infections:

1st week of life 50 mg/kg twice daily

Otherwise 50 mg/kg four times daily

CLINICAL PHARMACOLOGY:

  • Onset of Action: Rapid following intravenous administration or within 1 - 2 hours following oral administration.
  • Duration of Action: 2-4 hours.
  • Elimination: Predominantly renal. Time to washout approximately 6 - 8 hours following the last dose in healthy individuals.

Amoxicillin is bactericidal against susceptible organisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell wall mucopeptide. Amoxicillin has been shown to be active against most strains of the following microorganisms:

Aerobic Gram-Positive Microorganisms:

  • Enterococcus faecalis

  • Staphylococcus species (beta-lactamase-negative strains only). Staphylococci which are susceptible to amoxicillin but resistant to methicillin/oxacillin should be considered as resistant to amoxicillin.

  • Streptococcus pneumoniae

Aerobic Gram-Negative Microorganisms:

  • Escherichia coli (beta-lactamase-negative strains only)

  • Haemophilus influenzae (beta-lactamase-negative strains only)

  • Neisseria gonorrhoeae (beta-lactamase-negative strains only)

  • Proteus mirabilis (beta-lactamase-negative strains only)

Amoxicillin diffuses readily into most body tissues and fluids, with the exception of brain and spinal fluid, except when meninges are inflamed.

CONTRAINDICATIONS:

  1. A history of allergic reaction to any of the penicillins.

WARNINGS:

Anaphylaxis

Penicillins are a common cause of anaphylactic reactions.

Pseudomembranous colitis

Pseudomembranous colitis has been reported with nearly all antibacterial agents, including amoxicillin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea subsequent to the administration of antibacterial agents.

Hepatic Side Effects

Hepatic events have been reported predominantly in males and elderly patients and may be associated with prolonged treatment. These events have been very rarely reported in children. Signs and symptoms usually occur during or shortly after treatment but in some cases may not become apparent until several weeks after treatment has ceased. These are usually reversible.

PRECAUTIONS:

General:

Prescribing amoxicillin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria.

Laboratory Tests:

No tests in addition to routine ICU tests are required.

Drug/Laboratory Test Interactions:

None noted.

IMPORTANT DRUG INTERACTIONS IN ICU:

None of significance.

ADVERSE REACTIONS:

General:

Serum sickness like reactions, anaphylaxis.

Gastrointestinal:

Nausea, vomiting, diarrhoea, and haemorrhagic/pseudomembranous colitis. Hepatic dysfunction including cholestatic jaundice, hepatic cholestasis and acute cytolytic hepatitis have been reported.

Hepatic:

Increased serum aspartate aminotransferase. Hepatic dysfunction, including cholestatic jaundice, hepatic cholestasis and acute cytolytic hepatitis have been reported.

Neurological:

Reversible hyperactivity, agitation, anxiety, insomnia, confusion, convulsions, behavioural changes, and/or dizziness have been reported rarely.

Dermatological:

Stevens-Johnson Syndrome, exfoliative dermatitus, toxic epidermal necrolysis, acute generalised exanthematous pustulosis, hypersensitivity vasculitis and urticaria have been reported.

Haematological:

Anaemia, including haemolytic anaemia, thrombocytopaenia, thrombocytopenic purpura, eosinophilia, leukopaenia, and agranulocytosis have been reported during therapy with penicillins.